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ABSTRACT 
Two novel prodrugs of amoxicillin and cephalexin (amoxicillin ProD 1 
and cephalexin ProD 1, respectively) were designed and synthesized to 
improve the stability and bitter sensation of their parent drugs. The in 
vitro susceptibility for both prodrugs was determined against 
Escherichia coli, staphylococcus epidermidis, staphylococcus aureus, 
Klebsiella pneumonia, streptococcus group A and streptococcus group 
B, and was compared to that of their active parent drugs.The 
antibacterial screening demonstrates that amoxicillin ProD 1 and 
cephalexin ProD 1 were found to be active and are considered among a 
small number of prodrugs that have therapeutic activity themselves 
before undergoing interconversion via enzymatic or chemical reaction 
to their corresponding active parent drugs. Both prodrugs exhibit their  
antibacterial activity against different types of bacterial strains due to the presence of β-
lactam ring in their structures. In addition, it is expected that these novel prodrugs will be 
much more stable in aqueous media than their corresponding active parent drugs due to the 
fact that the chemically sensitive amine group contained in the active parent drug structures is 
replaced with an amide, more chemically stable group, in the corresponding prodrugs. 
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1. INTRODUCTION 
1.1 Historical Background 
Infectious diseases are as old as lifetime itself. In 1910, Ehrlich synthesized salvarsan for 
treatment of syphilis to become the first antimicrobial drug in the world. In 1929 Fleming 
observed that bacterial growth was inhibited in the presence of Penicillium notatum. This 
observation makes penicillin the first broad antibiotic used in 1940s and led to its broad use 
during World War II. In 1935 Domagk developed sulfonamides, followed by the discovery of 
quinolones (e.g. Ciprofloxacin) in 1962 and oxazolidinones in 1979. 
[1-3] 
 
Figure 1 shows the timeline discovery of antibiotics with natural and synthetic origins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Timeline discovery of antibiotics
[3]
 
 
1.1 Discovery of Penicillin 
Sanderson and Robert independently noted that bacterial growth was prevented in the 
presence of fungi.
[4]
 The same observation was made by Tyndall in 1876 upon surmising the 
antagonism of bacterial growth due to the low oxygen level, which presumably was 
consumed by fungi. 
 
The first in vitro work was done by Cornil and Babes. Both scientists assessed the microbial 
inhibition and antagonism and explained this observation as a substance produced by one 
microorganism that may serve as an antagonist for the growth of another.
[4, 5] 
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In 1887 Garre observed that the staphylococcus pyogens growth was inhibited in the presence 
of Bacillus fluorescence. Another observation which was noted by Duschesne in 1897 is the 
antagonism between Penicillium and Escherichia bacteria. In 1941, Waksman named these 
observations as antibiosis.
[4]
 The true story began in 1928 by Fleming who observed an 
accumulation of staphylococcus aureus culture plates on one edge of his laboratory board and 
a colony of mold growing on the other side of the plate where Staphylococcus aureus around 
this area disappeared.  Fleming was interested in this observation and he sub-cultured the 
mold and studied it. The culture of the mold was in nutrient broth and was for a period of 
eight days at room temperature. Fleming noticed that there was complete inhibition of growth 
of many bacteria. This fluid was first called mold juice and later Fleming named the active 
substance ―penicillin‖.[6-8] 
 
During this time period, Clutterbuck, Lovell and Raistrich extracted the active compound 
from the mold. They found that a pure compound could be separated by ether and watery 
acidic medium extractions. Upon evaporating the ether they recognized that the activity of the 
compound was diminished which led them to conclude that the active ingredient (penicillin) 
is unstable compound in acidic aqueous medium.
[7] 
 
1.. β- lactam Antibiotics Structure 
Structurally, β-lactam antibiotic molecules contain β -lactam nucleus, 6-amino penicillanic 
acid (6-APA) or 7-amino cephalosporinic acid (7-ACA), which provide a key for synthesis 
and modification (Figure 2). 
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Figure 2. Chemical structures of 6-aminopenicillanic acid and 7-aminocephalosporanic 
acid. 
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Novel β-lactam agents can be synthesized by linking a unique side chain to 6-APA. Early 
work by Sheehan produced penicillin V by acylation of 6-APA. Thereafter, in 1960 
methicillin was approved in the United States and became the first semisynthetic penicillin 
which is stable to enzymatic degradation, especially to penicillinase enzyme. 
 
In addition, in 1967 carbenicillin was produced as semisynthetic compound by adding a 
carboxyl group instead of the amino group of ampicillin.  
 
Abraham and Newton isolated a new family of β-lactam antibiotics from Cephalosporium 
acremonium called cephalosporin C which contains 7-ACA nucleus instead of 6-APA in 
penicillin.
[5] 
 
Chemical modification on β-lactam antibiotics provided many semisynthetic compounds. For 
example, various salts or esters of penicillin such as procaine and bezathine were synthesized 
and used for intramuscular injection due to their poor solubility in water. 
 
The reactive β-lactam ring present in this class of antibiotics made these agents unstable and 
very labile. Therefore, a variety of modifications on the nucleus led to changes in their 
chemical properties such as an increase in their stability in acidic and basic media, a decrease 
in their degradation by enzymes and a broader spectrum of activity.
[9] 
 
Penicillanic acid (Figure 2) represents the core structure of penicillin which upon conversion 
to its Na
+
 or K
+
 salts provides soluble compounds and upon substitution with benzathine 
gives insoluble agents. The most important modification in the structure of the core is on the 
R group (Figure 3) because the β-lactam ring‘s reactivity and stability depend on the side 
chain substitution. This is essential for the action of β-lactam antibiotics to act as anti-
bacterial agents. 
 
The first semisynthetic modification was changing the side chain R in penicillin G with other 
side chains such as in phenoxyethyl, phenoxymethyl, where the β-lactam ring is less reactive 
to H
+
 due to the change of the electron distribution and a creation of more stable entities.    
 
In the basic chemical structure of cephalosporin which has a basic structure as penicillin, but 
it has six-member dihydrothiazine ring instead of the thiazolidine ring in penicillin both R1 
and R2 provide opportunity for essential side chains modifications which result in changes of 
different properties of the agents (Figure 3). 
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Figure 3. Penicillin’s and cephalosporin’s core structures, where the R, R1 and R2 
groups are variable.
[1] 
 
The main entity contained in both structures, penicillins and cephalosporins, and essential for 
the antibacterial activity is the β-lactam ring. This entity interacts with active sites in the 
bacteria and produces the desired antibacterial effect. This happens when C—N bond in the 
β-lactam opens and binds to a carbon atom in the bacteria‘s site of action by a covalent bond, 
resulting in an acylation of an important group needed for cell wall synthesis.
[1]
 
 
1.4 Mechanism of Action 
Cell wall in bacteria is an important structure in both Gram positive and Gram negative 
bacteria because of stress bearing and shape maintaining function.
[10]
 It is a complicated 
structure which is composed of multiple types of polymers, peptidoglycans, teichoice acid 
and lipopolysaccharides. However, the most important among these is peptidoglycan because 
it is essential for cells living under normal growth conditions. 
 
Transpeptidase enzyme interacts with the peptide linkage contained in the pentapeptide chain 
of the uncrossed linked peptidoglycan (terminal D-alanine). This interaction results in D–
alanine release and an acyl enzyme intermediate formation. 
 
Penicillin behaves like terminal D-alanine in the pentapeptide chain. The CO-N bond in β-
lactam structure crosses bond to the peptide bond during trans-peptidation. Thus new 
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transition state is formed and peptide bond is cleaved; when the enzyme cleaves the β-lactam 
ring forms a stable pencicilloyl-enzyme complex resulting in an inhibition of the 
transpeptidase enzyme.
[11, 12]
  
 
1.5 Amoxicillin 
In 1972 amoxicillin was synthesized in the UK. It has the same activity as ampicillin, but 
with higher bioavailability.
[13]
 Later a combination of amoxicillin with clavulanic acid was 
developed to introduce better oral bioavailability and broad spectrum activity against a 
variety of pathogens that produce β-lactamase enzyme.[14] 
 
As amoxicillin acts on cell wall of bacteria; it has bactericidal action against both gram 
positive and gram negative. Amoxicillin is used for many indications; treatment middle ear 
infection 
[15]
 laryngitis, bronchitis, pneumonia,
[16]
 and typhoid fever.
[15]
 
Amoxicillin is the most commonly  prescribed antibiotic for children, it is well absorbed after 
oral administration, used for treatment in a variety of infections not only for broad spectrum 
also for outstanding advantage compared to other penicillins with higher bioavailability of  
70-90%, and reaches Cmax within 1-2 hours. 
[15]
 Amoxicillin is widely distributed in the body 
and the apparent volume of distribution is 0.26 - 0.31mL/kg, it has half-life 1-1.5 hours. 
[17]
 It 
is excreted by the renal route and approximately 10-25% of the drug is bio-transformed into 
penicillanic acid. 
[15]
 
 
1.6 Cephalosporin 
Cephalosporins are related to penicillin β-lactam antibiotics; they act on cell wall of bacteria; 
interfering and lysing bacterial cell wall. This action is achieved by drug‘s crossing and 
binding to penicillin binding protein in the bacteria‘s cell wall (site of action).[18] 
 
Cephalosporin has no activity against enterococcus due to low affinity on penicillin binding 
protein. However, it has different activities against Pseudomonas aeruginosa and 
Enterobacteriacea, because of differences in binding on the active site located on the 
bacteria‘s cell wall.[19] 
 
Structure activity relationship and differences in side chain substitution at C7 position of the 
main core of cephalosporins can lead to various pharmacokinetics properties, spectra of 
activity, and β-lactamase stability. 
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It was reported that alteration of the substituent on C7 by the addition of methoxy group 
(cephamycin) or replacing the sulfur in dihydrothiazine ring with oxygen (moxalactam) leads 
to an increase in stability against enzymatic hydrolysis by β-lactamase.[18] 
 
Conventional oral suspensions and solutions of antibiotics dispensed as powders need to be 
reconstituted with water at the time of use. The reconstitution process of penicillins and 
cephalosporins allows acceptable but short life of the antibacterial agent with storage in 
refrigerator.
[20]
 The highly strained β–lactam ring that presents in both penicillin and 
cephalosporin structures is unstable in solution; hydrolysis occurs and as a result the 
antibacterial agent loses its activity.  
 
The degradation process is an irreversible chemical change in the organic molecular structure 
of the antibacterial agent.
[21]
 The degradation of penicillin can occur in different conditions; 
acidic or alkaline, in the presence of weak nucleophile as water and β-lactamase enzyme. 
Therefore, methods to increase the stability of penicillins and cephalosporins are crucially 
needed.  
 
The palatability of the active ingredient of a drug is a significant obstacle in developing a 
patient friendly dosage form. Organoleptic properties such as taste are an important factor 
when selecting a certain drug from the generic products available in the market that have the 
same active ingredient. The problem of the bitter taste of drugs in pediatrics and geriatrics 
formulations still creates a challenge to pharmacists. Thus, different strategies should be 
developed in order to overcome this serious problem.
[22-27]  
 
In the past few years we have been engaging in studying intramolecularity and concluded that 
there is a need to research the mode and action by which intramolecular processes proceed in 
order to utilize them in the design of novel prodrugs. Unraveling the mechanism of 
intramolecular processes such as enzyme models would open the door widely for a precise 
design of chemical devices to be exploited as promoities to be covalently attached to 
commonly used drugs for providing prodrugs with better bioavailability and less adverse 
effects than their corresponding active parent drugs.  
 
Among the intramolecular processes (enzyme models) that we have calculated using quantum 
mechanics and molecular mechanics methods are: (1) proton transfer between two oxygens 
and proton transfer between nitrogen and oxygen in Kirby‘s enzyme model; (2) acid-
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catalyzed hydrolysis in Kirby‘s N-alkylmaleamic acids; (3) proton transfer between two 
oxygen atoms in Menger‘s rigid hydroxy-acids; (4) acid-catalyzed lactonization of hydroxy-
acids as investigated by Cohen and (5) cyclization in dicarboxylic semi-esters as researched 
by Bruice and Pandit. Prodrugs in which the above mentioned enzyme models were utilized 
as linkers which covalently are attached to drugs having poor bioavailability or/and bitter 
sensation were designed and synthesized. The controlled (programmed) intraconversion rates 
of the novel designed prodrugs to release their active parent drugs are solely determined on 
the structural features of the linker and there is no need to an involvement of metabolic 
enzymes.
[28-64]
  
 
For example, unraveling the mechanism for the intramolecular proton transfer in Kirby‘s 
acetals.
[65-73]
 revealed a design and synthesis of novel prodrugs of aza-nucleosides for the 
treatment of myelodysplastic syndromes,
[74]
 and statins to lower cholesterol concentration in 
the systemic blood circulation.
[75]
 In these cases, the prodrug linker was covalently linked to 
the hydroxyl group in the active drug such that the prodrug has the capability to undergo a 
chemical cleavage upon reaching a physiological environment such as stomach, intestine, 
and/or blood circulation, with rates that are determined only by the structural features of the 
pharmacologically inactive linker (Kirby‘s acetal). Kirby‘s N-alkylmaleamic acids enzyme 
model.
[65-73]
 was also studied as linkers in the design of tranexamic acid prodrugs for treating 
bleeding conditions 
[76]
 acyclovir prodrugs for the treatment of Herpes Simplex,
[77]
 and 
atovaquone prodrugs as antimalarial agents.
[78-80] 
The intramolecular proton transfer in 
Menger‘s Kemp acid enzyme model.[81-85] was also explored and used for the design of 
dopamine prodrugs for Parkinson‘s disease cases. [86] In addition, dimethyl fumarate prodrugs 
for treating psoriasis cases were also designed and developed..
[87] 
 
The novel prodrugs approach was also applied for masking the bitter sensation of the pain 
killer paracetamol, the anti-hypertensive agent atenolol, the decongestant phenylephrine, the 
anti-inflammatory agents, diclofenac and mefenamic acid and the bitter antibacterials 
cefuroxime, amoxicillin and cephalexin.
[88-95]
The role of the linker in the antibacterial 
prodrugs is to block the amine or/and hydroxyl groups which are believed to be responsible 
for the drug bitter sensation. The difference between the designed antibacterials prodrugs and 
their active parent drugs is that the free amine moiety in the active drug is replaced with an 
amide group. Replacing the amine with an amide eliminate the capability of the antibacterial 
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to form hydrogen bonds with the bitter taste receptor, thus masking the bitter sensation of the 
parent antibacterial drug.  
 
Based on DFT calculations and experimental values obtained from intramolecular acid 
catalyzed hydrolysis in nine N-alkylmaleamic acids, we have designed and synthesized two 
prodrugs of amoxicillin (amoxicillin ProD 1) and cephalexin (cephalexin ProD 1) by reacting 
the antibacterial agent with a maleic anhydride linker (Figure 4) aiming to: (1) improve the 
stability and aqueous solubility of the antibacterial agent (2) provide antibacterial agents 
lacking bitter sensation.  
 
The two synthesized prodrugs were designed such that the amine group in the active parent 
drugs is replaced with the more stable amide group.  
 
In this manuscript we report the antibacterial spectrum of two novel prodrugs, amoxicillin 
ProD 1 and cephalexin ProD 1. 
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Figure 4. Synthesis of amoxicillin ProD1 and cephalexin ProD 1. 
 
 1.7 Antimicrobial Activity of Amoxicillin and Cephalexin  
1.7.1 Amoxicillin Activity 
Penicillins have been divided into classes based on their spectrum of activity; the first agent 
that was used clinically to treat infections is the natural penicillin (penicillin G), but after the 
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emergence of penicillinase in staphylococci penicillins became inefficient for these 
organisms. Therefore, development of penicillinase resistant-penicillins was initiated; this led 
to the development of three categories of penicillins: the aminopenicillins, carboxypencillins 
and ureidopencillin.
[96] 
 
Aminopenicillins was the first class of penicillin antibiotic that has activity to both gram 
positive and gram negative bacteria; ampicillin compared to natural penicillin has more 
activity against enterococci, but somewhat less activity against pyogens, streptococcus 
pneumonia, and Neisseria species. On the other hand, it has some activity against E.coli, 
proteus Mirabella, salmonella, shigella, listeria, which are gram negative bacteria.
[96] 
 
Amoxicillin has shown to be effective against a variety of infections, which are caused by 
gram positive and gram negative bacteria in humans and in animals. 
[97]
 Amoxicillin has a 
higher activity against gram positive than gram negative microorganisms.
[98]
 In addition,  it 
has greater efficacy relative to penicillinV and other antimicrobial such as ampicillin 
[15]
 and 
cefuroxime.
[99] 
 
 Different study reports showed that amoxicillin was effective at MIC in the range of 0.06 
μg/mL- 4 μg/mL against variety of microorganism, except staphylococcus .epi 64 μg/mL and 
staphylococcus aureus MIC up to 256 μg/mL.[100] 
 
In one study, amoxicillin and ampicillin showed that the kill rates for amoxicillin was higher 
than ampicillin for E.coli, and the rate of killing was the same for both agents for  
Staphylococcus Aureus, but amoxicillin showed longer bacteriostatic  phase which was not 
observed with ampicillin.
[15] 
 
In another study an investigation on the antibacterial activity of amoxicillin and ampicillin 
against 30 isolates of each of proteus mirabilis, Klebsiella, E.coli, Enterobacter and idol 
positive proteus was carried out, and the results obtained are as follows:  89% of the E.coli 
strains were inhibited by both drugs at 10 μg or less per mL, whereas only 5μg or less were 
sufficient in the case of Proteus. mirabilas. On the other hand, high response of resistance to 
amoxicillin and ampicillin was seen among strains of Klebsiella, enterobacter and idol 
positive species.
[101]
 
 
In addition, other studies have demonstrated that amoxicillin was quite active against group A 
hemolytic streptococci, penicillin G susceptible staphylococcus aureus and pneumococci,  
www.wjpr.net                                   Vol 4, Issue 09, 2015.                                            
           
 
 
344 
Rafik et al.                                                             World Journal of Pharmaceutical Research 
only 28% of S. aureus  isolates which were resistant to 50 μg of penicillin G per mL were 
susceptible at 50 μg/mL or less to amoxicillin, 76% of  p. mirabilas isolates were susceptible 
to amoxicillin at 1.56 μg/mL or less and 20% showed resistant to 12.5 μg/mL or more, 75% 
of E.coli isolates were susceptible to 6.65 μg/mL or less and most of the remaining isolates 
were resistant to 50 μg/mL or more. [102] 
 
1.7.2 Cephalexin Activity 
First generation cephalosporins are cefazolin, cephapirin and cephalothin for intravenous use 
and cephalexin, cephradine, and cefadroxil which are used orally.  All of these 
cephalosporins are similar in spectrum of activity. They have high activity against gram-
positive cocci. They have low activity against gram negative bacteria. In addition, most 
strains of Escherichia coli, Klebsiella species, and Proteus mirabilis are sensitive to this class 
of drugs. They have no activity against methicillin-resistant Staphylococcus aureus (MRSA) 
and methicillin-resistant Staphylococcus epidermidis (MRSE), as well as enterococci, 
Listeria monocytogenes, Bacteroides fragilis, Citrobacter, Enterobacter, Proteus (other than 
mirabilis), Providencia, Pseudomonas, and Serratia organisms. Gram-positive anaerobes like 
Peptostreptococcus and non-penicillinase producing Bacteroides species are usually 
sensitive.
[18] 
 
Cephalexin is used for the treatment of the upper and lower respiratory tract infections, 
genitourinary system, skin, soft tissue, bones, joints and many other infections due to 
susceptible organisms.
[103]
 
  
EXPERIMENTAL 
2.1. Media Preparation 
Brain heart infusion agar, Muller Hinton agar (Becton, Disckinson and company sparks USA) 
and nutrient broth (hemedia laboratories Pvt. Ltd) were prepared in concentrations of 52 
gm/L, 38 gm/L and 13 gm/L, respectively. 
 
2.2. Preparation of the Buffer Solution 
Buffer solution (pH=7.4) was prepared by dissolving 0.68 gm of potassium dihydrogen 
phosphate in100 mL water, then NaOH was added and the solution was stirred. pH meter 
model HM-30G: TOA electronics™ was used to measure the pH value for all buffers and 
reaction media used in this study. 
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2.3 Test Microorganisms 
Reference strains obtained from American Type Culture Collection (ATCC) were used 
(Staphylococcus aureus (ATCC 25923), Staphylococcus epidermidis (ATCC 12228), 
Escherichia coli (ATCC 25922), Klebsiella pneumonia (ATCC 700603), 
Streptococcuspyogens (ATCC 19615), and Streptococcus group B obtained from 
microbiological labs (Al-Quds University). 
2.3.1 Preparation of Inocula 
Part of an isolated bacterial colony was inoculated in 5 mL nutrient broth & incubated for 24 
hours at 37
o
C, the growth turbidity in nutrient broth was adjusted by further incubation or 
dilution with sterile physiological saline; after comparison with that of a McFarland 
nephlometer  tube no. 0.5 (10
8 
cfu/mL) using spectrophotometer at 625 nm (optical density of 
0.08-0.1) 
 
2.4 Antimicrobial Activity Screening Methods 
2.4.1 Disk Diffusion Method  
With a sterile cotton applicator 10
8 
cfu/mL of each bacterial strain was swabbed on Muller 
Hinton agar (for Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and 
Klebsiella pneumonia) while brain heart infusion agar was used for Streptococci spp.) in the 
following manner:  
1. The cotton applicator was dipped into the bacterial suspension, rotated several times and 
pressed against the inside wall of the tube to remove excess inoculum. 
2. The agar plate was then streaked in three different directions and around the agar margin 
to ensure even distribution of the inoculum. 
3. The plates were left to dry for 3-5 minutes. 
4. Using sterile forceps the disks, which contain prodrugs, drugs, negative control were then 
distributed evenly on the surface of the agar plates. 
5. The plates were incubated upside-down at 37 oC.  
6. The inhibition zone around each disk was measured using a transparent ruler. 
 
2.4.2 Broth Dilution Method  
2.4.2.1 Preparation of Media 
For each strain 13 tubes, each contains 9.9 mL Muller Hinton broth were prepared and 
autoclaved. 
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2.4.2.2 Preparation of the Active Ingredients Dilutions 
The two prodrugs amoxicillin ProD 1 and cephalexin ProD 1 along with their active parent 
drugs, pure standards > 99% of amoxicillin and cephalexin, were commercially available 
from Sigma Aldrich and were used as positive control. 500 mg of each drug and prodrug 
were dissolved in 10 mL buffer solution pH 7.4, that has no effect on tested microorganisms 
and the prodrugs have maximum stability, to give a final concentration of 50 mg/mL. Then 
several dilutions of stock solution were prepared as shown in Table 1.
[104] 
 
Table 1. Dilutions of active ingredients  
Tube 
No. 
Volume taken from 
stock solution (50 
mg/mL) in mL 
Buffer 
(mL) 
Final 
concentration 
mg/mL 
Volume 
of broth 
in mL 
Final volume 
added to each 
tube in mL 
1 1 0 50 9.7 0.3 
2 1 0 50 9.75 0.25 
3 1 0 50 9.8 0.2 
4 1 0 50 9.9 0.1 
5 0.9 0.1 45 9.9 0.1 
6 0.8 0.2 40 9.9 0.1 
7 0.7 0.3 35 9.9 0.1 
8 0.6 0.4 30 9.9 0.1 
9 0.5 0.5 25 9.9 0.1 
10 0.4 0.6 20 9.9 0.1 
11 0.3 0.7 15 9.9 0.1 
12 0.2 0.8 10 9.9 0.1 
13 0 1 0 9.9 0.1 
 
The experiment was repeated with Klebsiella, which required lower concentrations to find 
MIC and MBC. Broth tubes containing the active ingredients with different concentrations 
were prepared as shown in the Table 2. 
 
Table 2. Dilutions of active ingredients used for Klebsiella 
Tube No. 
Stock solution 
50mg/mL 
Buffer (mL) 
Final concentration 
mg/mL 
Final concentration 
mg/0.1mL 
1 1 0 50 5 
2 0.9 0.1 45 4.5 
3 0.8 0.2 40 4 
4 0.7 0.3 35 3.5 
5 0.6 0.4 30 3 
6 0.5 0.5 25 2.5 
7 0.4 0.6 20 2 
8 0.3 0.7 15 1.5 
9 0.2 0.8 10 1 
10 0.1 0.9 5 0.5 
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11 0.05 0.95 2.5 0.25 
12 0.025 0.975 1.25 0.125 
13 0 1 0 0 
 
2.4.2.3 Incorporation of Active Ingredients into Media 
For the incorporation of  the active ingredients  into media, 13 broth tubes each contains 
broth volume as shown in Tables 3 and 4, into broth tube No. 1, 300 μL (0.3 mL) of stock 
solution was added into broth tube No. 2, 250 μL was added and 200 microliter into broth 
tube No. 3. The procedure was repeated for the remaining dilutions by adding 100 μL (0.1 
mL) for each tube, the final concentrations of the active ingredients in broth are shown in 
Tables 3 and 4. 
 
Table 3. Final concentration of the active ingredients, amoxicillin, cephalexin 
amoxicillin ProD 1 and cephalexin ProD 1 in the medium against Staphylococcus 
aureus, Staphylococcus epidermidis, Escherichia coli, Streptococcus pyogens group A, and 
Streptococcus group B. 
Tube No. 1 2 3 4 5 6 7 8 9 10 11 12 
Concentration  
microgram/mL 
150 125 100 50 45 40 35 30 25 20 15 10 
 
Table 4. Final concentration of the active ingredients amoxicillin, cephalexin amoxicillin 
ProD 1 and cephalexin ProD 1 used for Klebsiella. 
Tube No. 1 2 3 4 5 6 7 8 9 10 11 12 
Concentration  
microgram/mL 
50 45 40 35 30 25 20 15 10 5 2.5 1.25 
 
2.4.2.4 Determination of Minimum Inhibitory Concentration (MIC) 
All tubes were inoculated with 10 µL of the tested bacterial suspension; the tubes were then 
incubated for 24 hours at 37
o
 C. After incubation, the tubes were examined for turbidity, 
indicating a growth of microorganisms; the organism will grow in the negative control tube 
(tube No.13) that does not contain antimicrobial agent to inhibit growth. The lowest 
concentration of the active ingredient (drug or prodrug) that inhibits a growth of the 
organism, as detected by a lack of visual turbidity is designated as the MIC (Figure 5). 
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Figure 5. Broth dilution susceptibility test; the tube number 5 lacks of visual turbidity.  
 
MBC is interpreted to be at a tube that shows no growth on the agar plate for example Figure 
5 shows that MIC for the test illustrated in the figure in tube no. 5 is 45 microgram per mL; 
while MBC is checked by testing viable colonies in tubes 1-5.  
Therefore, after reading the results of MIC by recording the lowest concentration that inhibits 
the organism growth, the following procedure is followed 
1. Sub-culturing of all tubes which have no visible growth by spreading loop full over 
quarter of the agar plate. 
2. Incubation at 37 °C for overnight then reading the result and recording as follows: 
 Bacteriostatic if similar number of colonies are present 
 Partial bactericidal if reduced number of colonies are found 
 No growth indicates that the whole inoculums  have been killed  
 
3-RESULTS AND DISCUSSION  
Table 5 and Figures 6-9 illustrate the bacterial inhibition by amoxicillin, cephalexin, 
amoxicillin ProD 1 and cephalexin ProD 1. 
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Table 5. Amoxicillin, cephalexin, amoxicillin ProD 1 and cephalexin ProD 1 inhibition 
of bacteria, showing zone of inhibition diameter in (mm). 
Amoxicillin drug and amoxicillin ProD 1 (P value =.141) 
Cephalexin drug and cephalexin ProD 1 (P value=.003) 
 
 
Figure 6. Antibacterial activity of amoxicillin drug and amoxicillin ProD 1 against 
bacterial strain. 
 
 
Figure 7. Antibacterial activity of cephalexin drug and cephalexin ProD 1 against 
bacterial strain. 
Compound Staph. 
Epidermidis 
(G+) 
Staph. 
aureus 
(G+) 
Streptoc
occi. B 
(G+) 
Streptoco
cci. A 
(G+) 
Klebsiella 
 
(G-ve) 
E. coli 
 
(G-ve) 
Amoxicillin 
 
No inhibition 
zone 
44 mm 30 mm 40 mm No inhibition 
zone 
33 mm 
 
Amoxicillin 
ProD 1 
No inhibition 
zone 
30 mm 30 mm 26 mm No inhibition 
zone 
31mm 
Cephalexin 25 mm 44 mm 33 mm 37 mm 26 mm 29 mm 
Cephalexin 
ProD 1 
20 mm 40 mm 32 mm 30 mm 21 mm 24 mm 
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Figure 8. Percentage of amoxicillin ProD 1 to amoxicillin drug vs. bacterial strain. 
 
 
Figure 9. Percentage of cephalexin ProD 1 to cephalexin drug vs. bacterial strain. 
 
The combined results shown in Table 5 and Figures 6-9 revealed that the novel two prodrugs, 
amoxicillin ProD 1 and cephalexin ProD 1 have antibacterial activity against most bacterial 
strains tested with about the same potency as their active parent drugs, amoxicillin and 
cephalexin.  
 
Klebsiella showed resistance to amoxicillin drug and its prodrug amoxicillin ProD 1, since  
klebsiella is a gram negative bacteria, which exhibits resistance to amoxicillin drug, 
[101]
 and 
there is a need of clavulanic acid to overcome its resistance. 
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Staphylococcus epidermidis also showed resistance to amoxicillin drug and its prodrug, 
amoxicillin ProD 1 since it is β-lactamase positive. Cephalexin drug and its prodrug, 
cephalexin ProD 1 showed inhibition against all bacterial strains tested including Klebsiella 
pneumonia and E.coli, since cephalexin drug has a broader spectrum than amoxicillin. 
 
Figures 8 and 9 demonstrate the percentage sensitivity of the two novel prodrugs, amoxicillin 
ProD 1 and cephalexin ProD 1 to antibacterial parent drug, amoxicillin and cephalexin, 
respectively, against bacterial strains tested in this study. The results demonstrate that for 
amoxicillin ProD 1/amoxicillin drug: 94% against E.coli, 59% against strep. A, 100% against 
strep. B and 68% against staph. arues. (Figure 8). For cephalexin ProD 1/cephalexin drug: 
82% against E.coli, 80% against Klebsiella, 96% against streptococcus group. B, 81% against 
strep. A, 81% against staphylococcus. Epidermidis and 91% against staphylococcus. areus 
(Figure 9). 
 
3.1 Minimum Bactericidal Concentrations (MBC) and Minimum Inhibition 
Concentrations (MIC) 
In this study the MIC and MBC values for both amoxicillin ProD 1 and cephalexin ProD 1 
were determined and compared with the values obtained for their active parent drugs, 
amoxicillin and cephalexin, respectively.  
 
The MIC and MBC values obtained for the activity on strep. B, staph arues and strep. A 
demonstrated that amoxicillin drug is more potent than its prodrug, amoxicillin ProD 1, as 
indicated by the lower concentrations of the parent drug needed to inhibit and kill the bacteria 
compared to that of its prodrug. 
 
Moreover, it was found that amoxicillin drug has similar MIC value as its prodrug, 
amoxicillin ProD 1 against E.coli 10 μg/mL. This indicates that both drug and prodrug are 
equal in potency as they have the same MIC and MBC. 
[101-103]
 Further, the study revealed 
that amoxicillin drug has different MIC value than its prodrug against staphylococcus. Areus, 
for the parent drug the MIC value was 50 μg/ml which is similar to that reported in previous 
studies.
[101-103] 
 
On the other hand, cephalexin drug was found to be slightly more potent than its prodrug, 
cephalexin ProD 1, as indicated by the MIC and MBC values obtained for both. Tables 6 and 
7 demonstrate that the prodrug of cephalexin, cephalexin ProD 1, is more potent on all 
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bacteria tested than the prodrug of amoxicillin, amoxicillin ProD 1 as evident by the MIC and 
MBC values obtained for cephalexin ProD 1 which were less or equal to 150 μg/mL, whereas 
the values obtained for amoxicillin ProD 1 were all above 150 μg/mL. 
 
Table 6. MIC, MBC of amoxicillin drug and amoxicillin ProD 1. 
Bacteria 
Amoxicillin 
Drug 
 
Amoxicillin 
ProD 1 
 
 MIC MBC MIC MBC 
Streptococcus. Group B 100 100 >150 >150 
E-coli 10 10 10 10 
Staphylococcus. areus 50 100 >150 >150 
Staphylococcus. 
Epidermidis 
--- ---- ---- ---- 
Klebsiella ----- ---- ---- ---- 
Streptococcus. group A 45 100 >150 >150 
MIC (P value =.004) and (P value =.098). MIC and MBC in μg/mL. 
 
Table 7. MIC, MBC of cephalexin drug and cephalexin ProD 1. 
Bacteria 
Cephalexin 
Drug 
 
Cephalexin 
ProD 1 
 
 MIC MBC MIC MBC 
Streptococcus. Group B 45 50 50 100 
E-coli 10 10 15 20 
Staphylococcus. areus 35 40 35 40 
Staphylococcus. 
Epidermidis 
45 125 50 150 
Klebsiella 5 5 10 15 
Streptococcus. group A 45 100 50 100 
MIC (P value =.004) and (P value =.098). MIC and MBC in μg/mL. 
 
4. CONCLUSIONS & FUTURE DIRECTION   
Two novel prodrugs of amoxicillin and cephalexin were designed and synthesized such that 
the amine group in the parent drugs is replaced with an amide group. This alteration made the 
two prodrugs much more stable to chemical reactions than their corresponding active parent 
drugs as judged by the stability study at a wide range of pH.  
 
The biological screening results revealed that the two novel prodrugs are among a small 
number of prodrugs having activity themselves prior to inter- or intraconversion via 
enzymatic or chemical reactions to release their corresponding active parent drugs. It is 
suggested that these novel prodrugs exhibit their antibacterial activity on different types of 
bacterial strains due to the presence of a β-lactam ring in their structures.  
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It is planned that in the near future the following steps will be taken: (1) determination of the 
exact MIC and MBC values for those experiments where the values were above 150 μg/mL, 
(2) an assessment of the antibacterial activity on other types of bacteria, and (3) in vivo 
testing of the two novel prodrugs.  
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